These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 9435407)

  • 1. Selective modulation of estrogen receptor action.
    Sadovsky Y; Adler S
    J Clin Endocrinol Metab; 1998 Jan; 83(1):3-5. PubMed ID: 9435407
    [No Abstract]   [Full Text] [Related]  

  • 2. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles.
    Baker VL; Draper M; Paul S; Allerheiligen S; Glant M; Shifren J; Jaffe RB
    J Clin Endocrinol Metab; 1998 Jan; 83(1):6-13. PubMed ID: 9435408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen, raloxifene, and the prevention of breast cancer.
    Jordan VC; Morrow M
    Endocr Rev; 1999 Jun; 20(3):253-78. PubMed ID: 10368771
    [No Abstract]   [Full Text] [Related]  

  • 4. Raloxifene: magic bullet for heart and bone?
    Gustafsson JA
    Nat Med; 1998 Feb; 4(2):152-3. PubMed ID: 9461183
    [No Abstract]   [Full Text] [Related]  

  • 5. Raloxifene: a selective estrogen receptor modulator.
    Scott JA; Da Camara CC; Early JE
    Am Fam Physician; 1999 Sep; 60(4):1131-9. PubMed ID: 10507743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next generation of SERMs being seen in clinic.
    Smigel K
    J Natl Cancer Inst; 1997 Jul; 89(13):913. PubMed ID: 9214669
    [No Abstract]   [Full Text] [Related]  

  • 7. Selective estrogen receptor modulators and postmenopausal women's health.
    Hol T; Cox MB; Bryant HU; Draper MW
    J Womens Health; 1997 Oct; 6(5):523-31. PubMed ID: 9356975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-specific estrogens--the promise for the future.
    Fuleihan GE
    N Engl J Med; 1997 Dec; 337(23):1686-7. PubMed ID: 9385130
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators.
    Fuchs-Young R; Howe S; Hale L; Miles R; Walker C
    Mol Carcinog; 1996 Nov; 17(3):151-9. PubMed ID: 8944075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor.
    Levenson AS; Jordan VC
    Cancer Res; 1998 May; 58(9):1872-5. PubMed ID: 9581827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective oestrogen receptor modulators: a new paradigm for HRT.
    Baynes KC; Compston JE
    Curr Opin Obstet Gynecol; 1998 Jun; 10(3):189-92. PubMed ID: 9619340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
    Grese TA; Cho S; Finley DR; Godfrey AG; Jones CD; Lugar CW; Martin MJ; Matsumoto K; Pennington LD; Winter MA; Adrian MD; Cole HW; Magee DE; Phillips DL; Rowley ER; Short LL; Glasebrook AL; Bryant HU
    J Med Chem; 1997 Jan; 40(2):146-67. PubMed ID: 9003514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone.
    Willson TM; Norris JD; Wagner BL; Asplin I; Baer P; Brown HR; Jones SA; Henke B; Sauls H; Wolfe S; Morris DC; McDonnell DP
    Endocrinology; 1997 Sep; 138(9):3901-11. PubMed ID: 9275080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raloxifene, a new selective estrogen receptor modulator.
    Goldfrank D; Haytoglu T; Frishman WH; Mohammad Z
    J Clin Pharmacol; 1999 Aug; 39(8):767-74. PubMed ID: 10434227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raloxifene induces neurite outgrowth in estrogen receptor positive PC12 cells.
    Nilsen J; Mor G; Naftolin F
    Menopause; 1998; 5(4):211-6. PubMed ID: 9872486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Estrogen receptor and selective estrogen receptor modulators (SERMs)].
    Shioi A; Nishizawa Y
    Nihon Rinsho; 1999 May; 57(5):1199-207. PubMed ID: 10361456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does raloxifene reduce breast cancer risk?
    Mattimoe D; Newton W
    J Fam Pract; 1999 Sep; 48(9):659-60. PubMed ID: 10498063
    [No Abstract]   [Full Text] [Related]  

  • 18. [Raloxifene: a selective modulator of estrogen receptors].
    van den Brûle FA; Kalbus MF; Gaspard UJ
    J Gynecol Obstet Biol Reprod (Paris); 1999 Dec; 28(8):788-99. PubMed ID: 10635481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
    Palkowitz AD; Glasebrook AL; Thrasher KJ; Hauser KL; Short LL; Phillips DL; Muehl BS; Sato M; Shetler PK; Cullinan GJ; Pell TR; Bryant HU
    J Med Chem; 1997 May; 40(10):1407-16. PubMed ID: 9154963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin.
    Gielen SC; Burger CW; Kühne LC; Hanifi-Moghaddam P; Blok LJ
    J Soc Gynecol Investig; 2005 Oct; 12(7):e55-67. PubMed ID: 16202921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.